Allarity Therapeutics, INC

Allarity Therapeutics announced the grant of a key U.S. patent for its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic, extending protection until April 2042.

Allarity Therapeutics, Inc. has amended its Management Services Agreement with Ljungaskog Consulting AB, owned by CEO Thomas H. Jensen, adjusting compensation and termination terms.

Allarity Therapeutics announced CEO Thomas Jensen will present clinical data on its dual PARP/WNT inhibitor, stenoparib, at the Precision Medicine Forum Europe 2026.

Allarity Therapeutics announced its API manufacturing campaign for stenoparib is on track for completion by Q3 2026, supporting pivotal trial development.

Allarity Therapeutics announced a Notice of Allowance from the USPTO for its DRP companion diagnostic specific to stenoparib, expected to grant exclusivity into 2039.

Allarity Therapeutics announced the presentation of two scientific posters at the AACR Annual Meeting 2026, highlighting stenoparib's potential in colorectal cancer and linking its companion diagnostic to improved survival in ovarian cancer.

Allarity Therapeutics reports Q1 2026 financial results, highlighting a $20 million capital raise and continued development of its stenoparib drug candidate.

Allarity Therapeutics reported a reduced net loss for the nine months ended September 30, 2025, while advancing its lead drug candidate stenoparib with FDA Fast Track designation and addressing internal control weaknesses.

Allarity Therapeutics reported a reduced net loss for the first half of 2025 and strategic advancements in its DRP platform, alongside a material weakness in internal controls and management changes.

Allarity Therapeutics announces its Q1 2025 financial results, highlighting a decrease in net loss compared to the previous year and providing updates on its clinical development programs and recent financial activities.

Allarity Therapeutics reported its third quarter 2024 results, including a significant impairment charge on intangible assets and ongoing efforts to secure additional funding.

Allarity Therapeutics reported its second quarter 2024 financial results, highlighting a reverse stock split, ongoing financial challenges, and an SEC investigation.

Allarity Therapeutics cut operating losses, resolved SEC matters, and advanced its PARP/tankyrase inhibitor stenoparib with Fast Track status and new trials while maintaining $14.7M cash at year-end.

Allarity Therapeutics streamlines operations to focus on stenoparib, a novel cancer therapeutic, while reporting financial results for the year ended December 31, 2024.

Allarity Therapeutics has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.

Allarity Therapeutics shifts its focus to stenoparib development in ovarian cancer, deprioritizing other assets and streamlining operations.

Thomas Jensen, CEO of Allarity Therapeutics, Inc., acquired 200,000 restricted stock units on January 28, 2026, as part of the company's equity incentive plan.

Jesper Hoeiland, a Director at Allarity Therapeutics, Inc., reported the acquisition of 25,000 shares of common stock on January 7, 2026.

Director Gerald W. McLaughlin acquired 45,000 shares of Allarity Therapeutics, Inc. common stock via a restricted stock unit grant.

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, was granted 133,333 restricted stock units.

Allarity Therapeutics CFO Jeffrey S. Ervin was granted 150,000 restricted stock units as part of the company's equity incentive plan.

Allarity Therapeutics, Inc. granted 133,333 restricted stock units to President and Chief Development Officer Jeremy R. Graff, vesting over three years.

Allarity Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Allarity Therapeutics is holding its annual meeting to vote on key proposals, including limiting officer liability and increasing shares for its equity incentive plan.

Allarity Therapeutics is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including a share decrease, a reverse stock split, and an amendment to limit officer liability.

Allarity Therapeutics has postponed its 2024 annual meeting of stockholders, originally scheduled for July 26, 2024, to a later date to be determined by the Board.

Allarity Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on July 26, 2024, to vote on several key proposals, including a share decrease, a reverse stock split, and an amendment to limit officer liability.

Allarity Therapeutics is holding a special virtual meeting on April 1, 2024, to seek stockholder approval for an amendment to its equity incentive plan and a reverse stock split to maintain its Nasdaq listing.

Allarity Therapeutics is offering 5,000,000 shares of common stock at an assumed price of $2.00 per share to raise capital while facing potential delisting from the Nasdaq Capital Market.

Allarity Therapeutics aims to raise up to $8 million through a best efforts offering of common stock, warrants, and pre-funded warrants to advance its stenoparib clinical trial and potentially repurchase Series A Preferred Stock.